Background: Soman, a potent irreversible acetylcholinesterase (AChE) inhibitor, induces delayed neuronal injury by reactive oxygen species (ROS). Midazolam is used in patients with pathologic effects of oxidative stresses such as infection, hemodynamic instability and hypoxia. We investigated whether midazolam protects the Central Nervous System (CNS) from soman intoxication. The present study was performed to determine whether midazolam protects B35 cells from ROS stress for the purpose of exploring an application of midazolam to soman intoxication.
Methods: Glucose oxidase (GOX) induced ROS stress was used in a B35 neuroblastoma cell model of ROS induced neuronal injury. To investigate the effect of midazolam on cell viability, LDH assays and fluorescence activated cell sorting (FACS) analysis was performed. Western blotting was used for evaluating whether Akt-phosphorylation is involved in cell-protective effects of midazolam.
Results: GOX derived ROS injury decreased cell viability about 1.6-2 times compared to control; midazolam treatment (5 and 10 µg/ml) dose-dependently increased cell viability during ROS injury. On western blots, Akt-phosphorylation was induced during pretreatment with midazolam; it was diminished during co-treatment with LY-294002, an inhibitor of Akt-phosphorylation. FACS analysis confirmed that the cell protective effect of midazolam is mediated by an anti-apoptotic effect. GOX-induced apoptosis was inhibited by midazolam and the finding was diminished by LY-294002.
Conclusions: Midazolam protects neuronal cells from GOX-induced ROS injury; this effect is mediated by an anti-apoptotic effect through Akt-phosphorylation. This shows that midazolam may be useful in soman intoxication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284740 | PMC |
| http://dx.doi.org/10.4097/kjae.2012.62.2.166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of the Protective Effects of Dexmedetomidine, Midazolam, Propofol, and Intralipid on Oxidative Stress and Inflammation in Rats with Lidocaine-Induced Toxicity.
J Inflamm Res
January 2025
Department of Anesthesiology, ICU & Perioperative Medicine Hazm Mebaireek General Hospital HMC, Industrial Area Ar-Rayyan, Doha, Qatar.
Aim: The aim of this study was to compare the effects of dexmedetomidine, midazolam, propofol, and intralipid on lidocaine-induced cardiotoxicity and neurotoxicity.
Methods: Forty-eight male Sprague-Dawley rats were randomly divided into six groups (n = 8 per group): control (C), lidocaine (L), lidocaine + dexmedetomidine (LD), lidocaine + midazolam (LM), lidocaine + propofol (LP), and lidocaine + intralipid (LI). Dexmedetomidine (100 µg/kg), midazolam (4 mg/kg), propofol (40 mg/kg), and intralipid (10 mg/kg) were administered intraperitoneally as pretreatment.
Consensus Guideline for Care of Patients in the Prehospital and Aerospace Settings with Exposures to Hydrazine and Hydrazine Derivatives.
Prehosp Emerg Care
January 2025
Department of Emergency Medicine, College of Medicine, The University of Arizona, Tucson, Arizona.
Objectives: Hydrazine (HZ) and Hydrazine Derivative (HZ-D) exposures pose health risks to people in industrial and aerospace settings. Several recent systematic reviews and case series have highlighted common clinical presentations and management strategies. Given the low frequency at which HZ and HZ-D exposures occur, a strong evidence base on which to develop an evidence-based guideline does not exist at this time.
View Article and Find Full Text PDFDexmedetomidine is Associated with Reduced In-Hospital Mortality Risk of Patients with Subarachnoid Hemorrhage Undergoing Surgery.
World Neurosurg
December 2024
Department of Anaesthesiology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China. Electronic address:
Article Synopsis
- The study examines the impact of sedatives, especially dexmedetomidine, on in-hospital mortality rates in patients with subarachnoid hemorrhage (SAH).
- The analysis utilized data from the MIMIC-IV database and found that dexmedetomidine significantly reduced in-hospital mortality compared to other sedatives like propofol and midazolam.
- The research concluded that choosing the right sedative is crucial in managing SAH, as dexmedetomidine not only improves outcomes but also shows a protective effect mediated by creatinine levels.
Acceptability of midazolam and melatonin as premedications for anxious children undergoing general anaesthesia: a qualitative interview study with children, caregivers and health professionals participating in the MAGIC trial.
Trials
December 2024
School of Clinical Dentistry, University of Sheffield, Sheffield, UK.
Background: The acceptability of a children's premedication, prior to general anaesthesia (GA), is fundamental to ensuring positive clinical- and patient-reported outcomes. Midazolam, the current standard premedication, is known to have an unfavourable side-effects profile and presents a degree of risk which is accepted due to a need for compliance. Melatonin is a functionally diverse hormone with anxiolytic properties that offer potential benefits over midazolam.
View Article and Find Full Text PDFA competing risk model analysis of dexmedetomidine of in-hospital mortality in subarachnoid hemorrhage patients.
Sci Rep
November 2024
Department of Anesthesiology, Longyan First Hospital Affiliated to Fujian Medical University, No.105, Jiuyi North Road, Xinluo District, Longyan, 364000, Fujian, China.
Subarachnoid hemorrhage (SAH) is a severe cerebrovascular disorder characterized by the sudden influx of blood into the subarachnoid space. The use of sedatives may be associated with the prognosis of SAH patients. We obtained SAH data from the MIMIC-IV database.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!